Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19025101 | CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 18964637 | GLYCOSYLATION METHOD INVOLVING TRIVALENT IODINE REAGENT | December 2024 | February 2025 | Allow | 2 | 0 | 0 | No | No |
| 18664971 | CD206 TARGETED DRUG DELIVERY VEHICLES CARRYING NOVEL BISPHOSPHONATE DRUG PAYLOADS VIA A DEGRADABLE LINKER | May 2024 | January 2025 | Allow | 8 | 1 | 0 | No | No |
| 18442232 | SYNERGISTIC FORMULATIONS OF ADENOSINE RECEPTOR MODULATING AGENTS AND ANTICHOLINERGICS | February 2024 | June 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18425648 | ALTERING CANCER CELLULAR FUNCTIONS THROUGH PROTON MOPPING | January 2024 | June 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18519408 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | November 2023 | February 2025 | Allow | 15 | 1 | 0 | No | No |
| 18516459 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | November 2023 | July 2025 | Allow | 19 | 2 | 0 | No | No |
| 18389006 | SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION | November 2023 | April 2025 | Allow | 17 | 1 | 0 | No | No |
| 18388753 | METHODS, KITS, AND COMPOSITIONS FOR PROCESSING EXTRACELLULAR MOLECULES | November 2023 | April 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18476506 | COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS | September 2023 | May 2025 | Abandon | 20 | 3 | 0 | No | No |
| 18371865 | FORMULATIONS OF PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE DRUGS | September 2023 | March 2025 | Allow | 18 | 1 | 0 | No | No |
| 18228969 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | August 2023 | January 2025 | Allow | 17 | 1 | 0 | No | No |
| 18345357 | METHODS FOR DECREASING THE INCIDENCE OF NECROTIZING ENTEROCOLITIS IN INFANTS, TODDLERS, OR CHILDREN USING HUMAN MILK OLIGOSACCHARIDES | June 2023 | February 2025 | Allow | 20 | 1 | 0 | No | No |
| 18304061 | COMPOSITIONS AND METHODS OF TREATING ACNE AND PHOTOAGING | April 2023 | February 2025 | Allow | 22 | 2 | 0 | No | No |
| 18131058 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | April 2023 | May 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18191901 | INORGANIC SALTS OF NICOTINIC ACID MONONUCLEOTIDE AS ANTI-AGING AGENTS | March 2023 | November 2024 | Abandon | 20 | 2 | 0 | No | No |
| 18028080 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT AND PREVENTION OF A RED BLOOD CELL DISORDER | March 2023 | March 2025 | Allow | 23 | 1 | 0 | No | No |
| 18183110 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | March 2023 | January 2025 | Allow | 22 | 2 | 0 | No | No |
| 18157545 | NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF | January 2023 | May 2025 | Abandon | 28 | 2 | 0 | Yes | No |
| 17945872 | METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA | September 2022 | October 2023 | Allow | 13 | 3 | 0 | Yes | No |
| 17910220 | TREATMENT FOR CORONAVIRUS INFECTION AND ASSOCIATED CYTOKINE TOXICITY | September 2022 | December 2024 | Allow | 27 | 1 | 0 | No | No |
| 17792484 | PROCESS OF PREPARING NUCLEIC ACID OLIGOMER | July 2022 | May 2025 | Allow | 34 | 0 | 0 | No | No |
| 17778406 | NUCLEIC ACID PURIFICATION METHOD | May 2022 | March 2025 | Allow | 34 | 0 | 0 | No | No |
| 17777149 | NUCLEIC ACID SEPARATION METHOD, DETECTION METHOD, NUCLEIC ACID PURIFICATION COLUMN AND METHOD OF PRODUCING SAME | May 2022 | July 2025 | Allow | 38 | 1 | 0 | No | No |
| 17638537 | STING INHIBITORS AND THEIR THERAPEUTIC USES | February 2022 | June 2025 | Allow | 40 | 1 | 0 | No | No |
| 17427134 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | February 2022 | June 2025 | Allow | 46 | 1 | 0 | No | No |
| 17583378 | ANTI-VIRAL AND ANTI-TUMORAL COMPOUNDS | January 2022 | June 2025 | Allow | 41 | 1 | 0 | No | No |
| 17562327 | METHODS OF USING HUMAN MILK OLIGOSACCHARIDES FOR IMPROVING AIRWAY RESPIRATORY HEALTH | December 2021 | December 2024 | Allow | 36 | 4 | 0 | Yes | No |
| 17620545 | AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME | December 2021 | June 2025 | Allow | 42 | 1 | 0 | No | No |
| 17552750 | NUCLEIC ACID CONJUGATES AND USES THEREOF | December 2021 | July 2025 | Allow | 43 | 3 | 1 | No | No |
| 17595984 | REDUCED NICOTINAMIDERIBOSIDES FOR THE TREATMENT/PREVENTION OF LIVER DISEASE | December 2021 | March 2025 | Allow | 40 | 1 | 0 | No | No |
| 17613197 | FORMULATIONS OF CYCLIC MACROMOLECULE-BASED NANOPARTICLES ENCAPSULATING SMALL MOLECULES | November 2021 | April 2025 | Allow | 40 | 1 | 0 | No | No |
| 17531336 | Cellulose Ester Composition and Articles Made Therefrom | November 2021 | March 2025 | Allow | 40 | 1 | 0 | No | No |
| 17610121 | POROUS CELLULOSE MICROPARTICLES AND METHODS OF MANUFACTURE THEREOF | November 2021 | May 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17609684 | MATERIALS AND METHODS FOR PRODUCING ARABINOXYLAN COMPOSITIONS | November 2021 | January 2025 | Allow | 38 | 1 | 0 | No | No |
| 17606149 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF PAIN | October 2021 | April 2025 | Allow | 41 | 1 | 0 | No | No |
| 17603021 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | October 2021 | April 2025 | Allow | 42 | 1 | 0 | No | No |
| 17389152 | APPARATUS, SYSTEM, AND METHOD FOR FACILITATING INTRANASAL TREATMENT OF A PATIENT | July 2021 | May 2025 | Allow | 45 | 1 | 0 | No | No |
| 17363983 | 5'-Cyclo-Phosphonate Modified Nucleotides | June 2021 | May 2025 | Allow | 47 | 2 | 0 | No | No |
| 17267271 | BIOHYBRID PEPTIDOGLYCAN OLIGOMERS | February 2021 | November 2024 | Allow | 45 | 1 | 1 | No | No |
| 17258414 | EXTRACTION OF POLYNUCLEOTIDES | January 2021 | April 2025 | Abandon | 51 | 2 | 1 | No | No |
| 16072647 | URIDINE PHOSPHORAMIDE PRODRUG, PREPARATION METHOD THEREFOR, AND MEDICINAL USES THEREOF | July 2018 | April 2020 | Allow | 20 | 2 | 0 | Yes | No |
| 15895872 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | February 2018 | January 2020 | Allow | 23 | 2 | 0 | No | No |
| 15879802 | DRUG FORMULATIONS | January 2018 | October 2019 | Allow | 20 | 1 | 0 | Yes | No |
| 15556982 | COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" - DEPENDENT SIGNALLING | September 2017 | June 2019 | Allow | 21 | 1 | 0 | No | No |
| 15528056 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | May 2017 | November 2019 | Allow | 30 | 3 | 0 | Yes | No |
| 15488368 | COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR | April 2017 | May 2019 | Allow | 25 | 2 | 0 | Yes | No |
| 15320089 | Composition Comprising a Combination of DNA Methylation Inhibitor and a Vitamin D Receptor Agonist for the Treatment of Drug Resistant Cancer or for the Prevention of Tumor Relapse | December 2016 | September 2018 | Allow | 20 | 2 | 0 | No | No |
| 15367552 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | December 2016 | April 2019 | Allow | 28 | 1 | 1 | No | No |
| 15315068 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | November 2016 | September 2018 | Allow | 21 | 2 | 0 | Yes | No |
| 15301851 | ANTI-TUMOR AGENT CONTAINING TAXANE COMPOUND, AND ANTI-TUMOR EFFECT ENHANCER | October 2016 | March 2025 | Abandon | 60 | 11 | 0 | Yes | Yes |
| 13245709 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | September 2011 | February 2012 | Allow | 5 | 0 | 0 | No | No |
| 13176297 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO | July 2011 | December 2011 | Allow | 5 | 0 | 0 | No | No |
| 12929793 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | February 2011 | July 2011 | Allow | 5 | 0 | 0 | No | No |
| 12858247 | BRANCHED WATER-SOLUBLE POLYMERS AND THEIR CONJUGATES | August 2010 | April 2012 | Allow | 20 | 2 | 1 | No | No |
| 12825051 | METHOD OF INCREASING TEAR PRODUCTION WITH PURINERGIC RECEPTOR AGONISTS | June 2010 | September 2011 | Allow | 15 | 1 | 0 | No | No |
| 12797327 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | June 2010 | March 2011 | Allow | 10 | 0 | 0 | No | No |
| 12662939 | MODULATION OF TELOMERE LENGTH IN TELOMERASE POSITIVE CELLS AND CANCER THERAPY | May 2010 | June 2011 | Abandon | 14 | 1 | 0 | No | No |
| 12598802 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION | March 2010 | April 2012 | Allow | 30 | 0 | 0 | Yes | No |
| 12659425 | OLIGO-AMINOSACCHARIDE COMPOUND | March 2010 | May 2012 | Allow | 26 | 0 | 0 | No | No |
| 12629387 | COMPOSITIONS AND METHODS FOR DOUBLE-TARGETING VIRUS INFECTIONS AND TARGETING CANCER CELLS | December 2009 | November 2011 | Allow | 23 | 1 | 0 | No | No |
| 12571899 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | October 2009 | June 2010 | Allow | 8 | 0 | 0 | No | No |
| 12086172 | PROCESS FOR THE PREPARATION OF POLY(ALKOXYLATED) OLIGONUCLEOTIDES | September 2009 | February 2012 | Allow | 44 | 0 | 0 | No | No |
| 12549117 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | August 2009 | April 2012 | Allow | 32 | 1 | 0 | No | No |
| 12461776 | CORE 2GLCNAC-T INHIBITORS | August 2009 | March 2012 | Allow | 30 | 1 | 0 | No | No |
| 12544523 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | August 2009 | January 2012 | Allow | 28 | 1 | 0 | No | No |
| 12441317 | PROCESS FOR THE PREPARATION OF AN (RP)-8-SUBSTITUTED CAMPS | August 2009 | July 2012 | Allow | 40 | 2 | 0 | No | No |
| 12504839 | PROCESS FOR PRODUCTION OF CRYSTAL OF PURINE NUCLEOSIDE COMPOUND | July 2009 | June 2011 | Allow | 23 | 0 | 0 | No | No |
| 12501750 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | July 2009 | September 2010 | Allow | 14 | 2 | 0 | No | No |
| 12446431 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | July 2009 | January 2012 | Allow | 33 | 1 | 0 | Yes | No |
| 12497271 | METHOD FOR THE EXTRACTION OF STARCH FROM CORN | July 2009 | December 2011 | Allow | 30 | 1 | 0 | No | No |
| 12496311 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | July 2009 | December 2011 | Allow | 30 | 1 | 0 | No | No |
| 12487265 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY | June 2009 | March 2010 | Allow | 9 | 1 | 0 | No | No |
| 12483855 | CYCLIC CARBONYL MONOMERS FUNCTIONALIZED WITH CARBOHYDRATES, POLYMERS DERIVED THEREFROM, AND METHODS OF PREPARATION THEREOF | June 2009 | June 2011 | Allow | 24 | 0 | 0 | No | No |
| 12470985 | USE OF ZWITTERIONIC POLYSACCHARIDES FOR THE SPECIFIC MODULATION OF IMMUNE PROCESSES | May 2009 | June 2011 | Allow | 25 | 2 | 0 | No | No |
| 12089120 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | April 2009 | March 2011 | Allow | 36 | 1 | 0 | No | No |
| 11718046 | COMPOSITION FOR THE TREATMENT OF OBESITY AND HYPERLIPIDEMIA | April 2009 | July 2012 | Allow | 60 | 2 | 0 | No | Yes |
| 12414288 | COLORIMETRIC-OXYCARBONYL PROTECTING GROUPS FOR USE IN ORGANIC SYNTHESES | March 2009 | March 2011 | Allow | 24 | 0 | 0 | No | No |
| 12402601 | NOVEL NUCLEOSIDE DERIVATIVES | March 2009 | November 2011 | Allow | 32 | 2 | 0 | Yes | No |
| 12398866 | ANTIVIRAL THERAPEUTIC AGENTS | March 2009 | March 2011 | Allow | 24 | 0 | 0 | No | No |
| 12375077 | 3'-ETHYNYLCYTIDINE DERIVATIVE | January 2009 | August 2011 | Allow | 31 | 1 | 0 | No | No |
| 12227256 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM | December 2008 | August 2011 | Allow | 33 | 2 | 0 | No | No |
| 12159477 | DERIVATIVES OF EPIRUBICIN, THEIR MEDICINAL APPLICATION AND PHARMACEUTICALY ACCEPTABLE FORMS OF DRUGS | November 2008 | January 2012 | Allow | 42 | 2 | 0 | No | No |
| 12281160 | FLUOROCYTIDINE DERIVATIVES AND COX-2 INHIBITORS FOR THE TREATMENT OF CANCER | November 2008 | April 2011 | Abandon | 31 | 1 | 0 | Yes | No |
| 11579660 | CONTENT DEPENDENT INHIBITORS OF CYTIDINE DEAMINASES AND USES THEREOF | October 2008 | December 2011 | Allow | 60 | 1 | 0 | No | No |
| 12285144 | LIPASE INHIBITORS | September 2008 | March 2010 | Allow | 17 | 1 | 0 | Yes | No |
| 12238586 | COMPOSITIONS AND METHODS FOR THE REGULATION OF HOMOCYSTEINE LEVELS WITHIN THE BODY | September 2008 | March 2011 | Allow | 30 | 2 | 0 | No | No |
| 12234478 | POSITRON EMISSION TOMOGRAPHY PROBES FOR IMAGING IMMUNE ACTIVATION AND SELECTED CANCERS | September 2008 | September 2011 | Allow | 36 | 1 | 0 | No | No |
| 10597398 | EFFICIENT METHOD TO SYNTHESIZE BENZYL GROUP-PROTECTED ALPHA-PENTAGALLOYLGLUCOSE (ALPHA-PGG) AND ITS ANALOGUES | September 2008 | March 2010 | Allow | 44 | 1 | 0 | Yes | No |
| 12281470 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | September 2008 | June 2011 | Allow | 34 | 1 | 1 | Yes | No |
| 12193600 | NYLON POLYRIBONUCLEOSIDES | August 2008 | February 2011 | Allow | 30 | 1 | 0 | No | No |
| 12223940 | NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | August 2008 | September 2010 | Allow | 25 | 0 | 0 | No | No |
| 12164900 | METABOLICALLY STABLE PUROMYCIN ANALOGS | June 2008 | August 2010 | Allow | 26 | 0 | 0 | Yes | No |
| 12143451 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | June 2008 | March 2011 | Allow | 33 | 1 | 1 | No | No |
| 11914093 | COMPOSITION AND METHODS FOR SKIN CARE | June 2008 | June 2011 | Allow | 43 | 2 | 0 | Yes | No |
| 12096463 | ANTIBACTERIAL AGENTS | June 2008 | March 2011 | Allow | 34 | 1 | 1 | Yes | No |
| 11989054 | IMPROVEMENTS TO ANALOGOUS COMPOUNDS OF 6-THIOGUANOSINE TRIPHOSPHATE, THEIR USE IN MEDICAL FIELDS AND PROCESSES FOR THEIR PREPARATION | June 2008 | September 2011 | Allow | 44 | 2 | 1 | No | No |
| 12126205 | FUNGAL PHYTOTOXIN FUSICOCCIN FOR THE TREATMENT AND DIAGNOSIS OF COAGULATION-CORRELATED PATHOLOGIES | May 2008 | December 2010 | Allow | 31 | 1 | 0 | No | No |
| 12123656 | POLYNUCLEOTIDE LABELING REAGENT | May 2008 | May 2010 | Allow | 24 | 0 | 0 | No | No |
| 12110997 | METHOD FOR CONVERSION OF CARBOHYDRATE POLYMERS TO VALUE-ADDED CHEMICAL PRODUCTS | April 2008 | December 2011 | Allow | 43 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEWIS, PATRICK T.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 43.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner LEWIS, PATRICK T works in Art Unit 1691 and has examined 231 patent applications in our dataset. With an allowance rate of 95.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner LEWIS, PATRICK T's allowance rate of 95.7% places them in the 87% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by LEWIS, PATRICK T receive 1.47 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by LEWIS, PATRICK T is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a -2.7% benefit to allowance rate for applications examined by LEWIS, PATRICK T. This interview benefit is in the 5% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 39.3% of applications are subsequently allowed. This success rate is in the 88% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 66.0% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 81.2% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 69.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 68.6% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 11.7% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.